牌带来
发表于 2025-3-25 06:18:13
Myositiscle weakness. Muscle biopsies from these patients reveal abundant CD4+ and CD8+ T cells. Importantly, as many as 25% of these patients may have co-existing myasthenia gravis and/or myocarditis. Although optimal treatment strategies remain to be defined, corticosteroids with or without other immunomodulating therapies are often effective.
arbovirus
发表于 2025-3-25 10:34:30
http://reply.papertrans.cn/84/8301/830082/830082_22.png
Generosity
发表于 2025-3-25 13:54:55
Benefit-Risk Considerationse therapeutic options, and, most importantly, patient values and preferences. Future research should aim to quantify risks in these special populations to ensure evidence-based decision-making that considers patient trade-offs between quality of life and survival.
FLAG
发表于 2025-3-25 18:12:12
http://reply.papertrans.cn/84/8301/830082/830082_24.png
抱狗不敢前
发表于 2025-3-25 23:20:15
Book 2021bination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumati
要塞
发表于 2025-3-26 01:37:59
http://reply.papertrans.cn/84/8301/830082/830082_26.png
accomplishment
发表于 2025-3-26 05:49:47
http://reply.papertrans.cn/84/8301/830082/830082_27.png
BLOT
发表于 2025-3-26 11:16:00
http://reply.papertrans.cn/84/8301/830082/830082_28.png
现实
发表于 2025-3-26 14:40:51
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritise effect of ICIs seen by rheumatologists. Inflammatory arthritis can have heterogeneous presentations, but, most commonly, presents as an oligoarthritis or polyarthritis. Tendons may also be involved, and imaging shows a variety of changes, including synovitis, joint effusions, tenosynovitis, enthes
ELUC
发表于 2025-3-26 19:38:57
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumaticatity. It remains unclear whether checkpoint inhibitor-related polymyalgia rheumatica represents the occurrence of a classic rheumatic disease or a new clinical variant with potentially different pathogenesis, clinical course, and treatment responsiveness. While these patients can present classically